Navigation Links
Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
Date:9/28/2007

urysmal dilatation. A pseudoaneurysm, also known as a false aneurysm, is an "out pouching" of the aorta involving a defect in the two innermost tissue layers or the aorta. True aneurysms, in contrast, are vascular out pouchings involving all three tissue layers of the aorta. Less common yet serious conditions such as a penetrating ulcer of the aorta or a fistula, which is an abnormal connection or passageway between the aorta and other organs, can cause fatal hemorrhage. Trauma from a fall or motor vehicle accident may cause the thoracic aorta to transect and rupture.

Left untreated, TAAs can burst or rupture, leading to severe internal bleeding, shock and death. Approximately half of all TAAs go undetected because patients do not experience symptoms. Presence of symptoms may depend on the location and size of the aneurysm and whether a dissection is present. Symptoms of aortic rupture or dissection can occur suddenly with severe, sharp pain in the chest or upper back. Patients who experience these symptoms should seek immediate medical attention.

Early detection of aortic aneurysms can prevent sudden death, therefore patients with a family history of aortic aneurysm or other connective tissue disorders should notify their physician about their risk of thoracic aortic aneurysm. Thoracic aneurysms can be easily diagnosed using simple imaging tests including MRI and CT scan. If the TAA is small (around four or less centimeters in diameter), the physician may simply recommend monitoring the size and shape of the aneurysm every six months while also addressing other risk factors such as high blood pressure to reduce the degree of pressure on the weakened area of the aneurysm. Large, symptomatic TAAs require prompt attention to prevent rupture and are typically treated by a vascular surgeon with either open surgical repair or less invasive, endoluminal graft repair as described in this respect.

About the Arizona Heart Institute

Since 1971, the Ari
'/>"/>

SOURCE The Arizona Heart Institute
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
2. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
3. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
4. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
5. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
6. Drug for Treatment of Heart Failure Does Not Improve Survival, Compared to More Widely-used Medication
7. deCODE Announces Positive Topline Results for Phase I Study of DG051 for the Prevention of Heart Attack
8. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
9. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
10. First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan
11. New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting
Post Your Comments:
*Name:
*Comment:
*Email: